Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis

医学 骨质疏松症 唑来膦酸 随机对照试验 物理疗法 双膦酸盐 相对风险 弗雷克斯 指南 特立帕肽 安慰剂 骨矿物 内科学 替代医学 置信区间 骨质疏松性骨折 病理
作者
William James Deardorff,Irena Cenzer,Brian T. Nguyen,Sei J. Lee
出处
期刊:JAMA Internal Medicine [American Medical Association]
卷期号:182 (1): 33-33 被引量:114
标识
DOI:10.1001/jamainternmed.2021.6745
摘要

Importance: The clinical decision to initiate bisphosphonate therapy for the treatment of osteoporosis requires balancing shorter-term harms and burdens (eg, gastroesophageal irritation or severe musculoskeletal pain) with longer-term benefits in reducing potential fractures. Objective: To assess the time to benefit (TTB) of bisphosphonate therapy for the prevention of nonvertebral and other fractures among postmenopausal women with osteoporosis. Data Sources: Randomized clinical trials (RCTs) were identified from systematic reviews commissioned by the US Preventive Services Task Force (1 review), the Agency for Healthcare Research and Quality (1 review), the Cochrane Library (2 reviews), and the Endocrine Society (1 review). Study Selection: Studies selected were RCTs involving postmenopausal women with a diagnosis of osteoporosis based on existing vertebral fractures or bone mineral density T scores of -2.5 or lower. The selection process was focused on studies of alendronate, risedronate, and zoledronic acid because they are guideline-recommended first-line agents for reducing nonvertebral fractures. Studies were excluded if they did not focus on women with a primary diagnosis of osteoporosis, had no placebo arm, or had a lack of data on time to fracture. Data Extraction and Synthesis: Random-effects Weibull survival curves were fitted and Markov chain Monte Carlo methods were used to estimate the absolute risk reduction (ARR) and TTB for each study. These estimates were pooled using a random-effects meta-analysis model. Main Outcomes and Measures: The primary outcome was the time to 3 different ARR thresholds (0.002, 0.005, and 0.010) for the first nonvertebral fracture. Secondary outcomes included the time to 4 ARR thresholds (0.001, 0.002, 0.005, and 0.010) for hip fracture, any clinical fracture, and clinical vertebral fracture. Results: Of 67 full-text articles identified, 10 RCTs comprising 23 384 postmenopausal women with osteoporosis were included either as the original RCT or part of subsequently published pooled analyses. Among the studies, the number of participants ranged from 994 to 7765, with mean (SD) age ranging from 63 (7) years to 74 (3) years and follow-up duration ranging from 12 to 48 months. The pooled meta-analysis found that 12.4 months (95% CI, 6.3-18.4 months) were needed to avoid 1 nonvertebral fracture per 100 postmenopausal women receiving bisphosphonate therapy at an ARR of 0.010. To prevent 1 hip fracture, 200 postmenopausal women with osteoporosis would need to receive bisphosphonate therapy for 20.3 months (95% CI, 11.0-29.7 months) at an ARR of 0.005. In addition, 200 postmenopausal women with osteoporosis would need to receive bisphosphonate therapy for 12.1 months (95% CI, 6.4-17.8 months) to avoid 1 clinical vertebral fracture at an ARR of 0.005. Conclusions and Relevance: This meta-analysis found that the TTB of bisphosphonate therapy was 12.4 months to prevent 1 nonvertebral fracture per 100 postmenopausal women with osteoporosis. These results suggest that bisphosphonate therapy is most likely to benefit postmenopausal women with osteoporosis who have a life expectancy greater than 12.4 months.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Andyvictory完成签到,获得积分10
1秒前
啦啦完成签到,获得积分10
1秒前
炸毛小猫咪完成签到 ,获得积分20
1秒前
高挑的寒天完成签到,获得积分10
2秒前
拼搏凝冬完成签到,获得积分10
2秒前
luqong完成签到,获得积分0
2秒前
2秒前
2秒前
3秒前
Emily完成签到,获得积分10
3秒前
无极微光的应助被577呀采纳,获得20
3秒前
HALO发布了新的文献求助10
3秒前
3秒前
3秒前
LQQy27完成签到,获得积分10
3秒前
qwdqwqwqwq发布了新的文献求助10
4秒前
深情中恶完成签到 ,获得积分10
4秒前
AstrLees完成签到 ,获得积分10
4秒前
隐形曼青的应助被小北采纳,获得10
5秒前
5秒前
海伦完成签到,获得积分10
5秒前
木林森发布了新的文献求助10
5秒前
Di喵喵完成签到,获得积分10
5秒前
IFevan完成签到,获得积分10
6秒前
6秒前
哦吼完成签到,获得积分10
6秒前
赵芳完成签到,获得积分10
6秒前
阳光蚂蚁完成签到,获得积分10
6秒前
郭擎擎完成签到,获得积分10
7秒前
7秒前
7秒前
星空发布了新的文献求助10
7秒前
8秒前
Youdge发布了新的文献求助10
8秒前
wojiaojzc完成签到,获得积分10
8秒前
Boyce完成签到,获得积分10
8秒前
JinFFyy完成签到,获得积分10
8秒前
焦糖布丁完成签到,获得积分10
8秒前
建成发布了新的文献求助20
8秒前
gyusbjshaxb完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180531
求助须知:如何正确求助?哪些是违规求助? 9570507
关于积分的说明 21812974
捐赠科研通 7776619
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557539
邀请新用户注册赠送积分活动 2479185